AVADEL PHARMACEUTICALS PLC (AVDL) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-02-12

Key Insights

Avadel Pharmaceuticals PLC (AVDL) was acquired by Alkermes plc in a transaction valued at $21.00 per share in cash plus a contingent value right (CVR) of $1.50 per share.
The transaction was structured as a court-sanctioned scheme of arrangement under Irish law, with Avadel becoming a wholly-owned subsidiary of Alkermes.
As part of the transaction, Avadel terminated its existing 'at-the-market' offering program and prepaid a $60.2 million royalty agreement with RTW Royalty II DAC.

Want the newest filings?

This analysis covers the filing from 2026-02-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-20

Avadel Pharmaceuticals has received court approval to proceed with the proposed scheme of arrangement under which Alkermes plc will acquire the entire issued and to be issued ordinary share capital of Avadel.
The court has directed interested parties to notify Avadel's solicitors by February 5, 2026 if they intend to appear at the Sanction Court Hearing scheduled for February 10, 2026 to support or oppose the application.
The acquisition is expected to close shortly after the court issues an order sanctioning the scheme, subject to the satisfaction of the conditions set forth in the transaction agreement.

Filed: 2026-01-12

Avadel Pharmaceuticals shareholders approved the acquisition of the company by Alkermes plc, with over 95% of shareholders voting in favor.
The approval includes amendments to Avadel's articles of association to facilitate the acquisition, as well as non-binding approval of executive compensation arrangements.
The acquisition is expected to close in the near future, subject to customary closing conditions.

Other reports for AVADEL PHARMACEUTICALS PLC

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.